UCL Discovery Stage
UCL home » Library Services » Electronic resources » UCL Discovery Stage

Identification and characterization of Nanobodies targeting the EphA4 receptor

Schoonaert, L; Rué, L; Roucourt, B; Timmers, M; Little, S; Chávez-Gutiérrez, L; Dewilde, M; ... Robberecht, W; + view all (2017) Identification and characterization of Nanobodies targeting the EphA4 receptor. Journal of Biological Chemistry , 292 (27) pp. 11452-11465. 10.1074/jbc.M116.774141. Green open access

[thumbnail of DeStrooper_JBCarticle.pdf]
Preview
Text
DeStrooper_JBCarticle.pdf - Published Version

Download (2MB) | Preview

Abstract

The ephrin receptor A4 (EphA4) is one of the receptors in the ephrin system that plays a pivotal role in a variety of cell-cell interactions, mostly studied during development. In addition, EphA4 has been found to play a role in cancer biology as well as in the pathogenesis of several neurological disorders such as stroke, spinal cord injury, multiple sclerosis, amyotrophic lateral sclerosis (ALS), and Alzheimer's disease. Pharmacological blocking of EphA4 has been suggested to be a therapeutic strategy for these disorders. Therefore, the aim of our study was to generate potent and selective Nanobodies against the ligand-binding domain of the human EphA4 receptor. We identified two Nanobodies, Nb 39 and Nb 53, that bind EphA4 with affinities in the nanomolar range. These Nanobodies were most selective for EphA4, with residual binding to EphA7 only. Using Alphascreen technology, we found that both Nanobodies displaced all known EphA4-binding ephrins from the receptor. Furthermore, Nb 39 and Nb 53 inhibited ephrin-induced phosphorylation of the EphA4 protein in a cell-based assay. Finally, in a cortical neuron primary culture, both Nanobodies were able to inhibit endogenous EphA4-mediated growth-cone collapse induced by ephrin-B3. Our results demonstrate the potential of Nanobodies to target the ligand-binding domain of EphA4. These Nanobodies may deserve further evaluation as potential therapeutics in disorders in which EphA4-mediated signaling plays a role.

Type: Article
Title: Identification and characterization of Nanobodies targeting the EphA4 receptor
Location: United States
Open access status: An open access version is available from UCL Discovery
DOI: 10.1074/jbc.M116.774141
Publisher version: http://doi.org/10.1074/jbc.M116.774141
Language: English
Additional information: © 2017 by The American Society for Biochemistry and Molecular Biology, Inc. Author's Choice—Final version free via Creative Commons CC-BY license.
Keywords: EphA4, VHH, inhibition, ligand-binding domain, phosphorylation, protein-protein interaction, receptor-tyrosine kinase, regeneration, single-domain antibody (sdAb,Nanobody)
UCL classification: UCL
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UK Dementia Research Institute HQ
URI: https://discovery-pp.ucl.ac.uk/id/eprint/1562084
Downloads since deposit
7,448Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item